Botanical Ingredient

References

• 1. The experimental study of Astragalus membranaceus on meridian tropsim: The distribution study of astragaloside IV in rat tissues.
  Chang YX, Sun YG, Li J, Zhang QH, Guo XR, Zhang BL, Jin H, Gao XM.J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Dec 12;911:71-5. doi: 10.1016/j.jchromb.2012.10.024. Epub 2012 Nov 3.
• 2. Astragaloside IV inhibited the activity of CYP1A2 in liver microsomes and influenced theophylline pharmacokinetics in rats.
  Zhang YH, Zhang YJ, Guo YL, Li WJ, Yu C.J Pharm Pharmacol. 2013 Jan;65(1):149-55. doi: 10.1111/j.2042-7158.2012.01579.x. Epub 2012 Aug 29.
• 3. Xiang-Qi-Tang and its active components exhibit anti-inflammatory and anticoagulant properties by inhibiting MAPK and NF-κB signaling pathways in LPS-treated rat cardiac microvascular endothelial cells.
  He CL, Yi PF, Fan QJ, Shen HQ, Jiang XL, Qin QQ, Song Z, Zhang C, Wu SC, Wei XB, Li YL, Fu BD.Immunopharmacol Immunotoxicol. 2012 Nov 21. [Epub ahead of print]
• 4. [Protective effects of astragaloside IV on high-glucose-induced damage of retinal ganglion cells].
  Hao M, Kuang HY, Fu Z, Gao XY, Li Y, Chen P, Wang Y.Zhonghua Yi Xue Za Zhi. 2012 Aug 14;92(30):2104-7. Chinese.
• 5. [Effects of the combination of active component extracts from Astragalus membranaceus and Panax notoginseng on apoptosis, reactive oxygen species and mitochondrial membrane potential of PC12 cells with oxidative injury].
  Huang XP, Liu XD, Deng CQ.Zhong Xi Yi Jie He Xue Bao. 2012 Oct;10(10):1127-34. Chinese.
• 6. Astragaloside IV inhibits oxidative stress-induced mitochondrial permeability transition pore opening by inactivating GSK-3β via nitric oxide in H9c2 cardiac cells.
  He Y, Xi J, Zheng H, Zhang Y, Jin Y, Xu Z.Oxid Med Cell Longev. 2012;2012:935738. doi: 10.1155/2012/935738. Epub 2012 Sep 25.
• 7. Astragaloside IV attenuates Toll-like receptor 4 expression via NF-κB pathway under high glucose condition in mesenchymal stem cells.
  Li M, Yu L, She T, Gan Y, Liu F, Hu Z, Chen Y, Li S, Xia H.Eur J Pharmacol. 2012 Dec 5;696(1-3):203-9. doi: 10.1016/j.ejphar.2012.09.033. Epub 2012 Oct 3.
• 8. Therapeutic effects of astragaloside IV on myocardial injuries: multi-target identification and network analysis.
  Zhao J, Yang P, Li F, Tao L, Ding H, Rui Y, Cao Z, Zhang W.PLoS One. 2012;7(9):e44938. doi: 10.1371/journal.pone.0044938. Epub 2012 Sep 17.
• 9. The effect of Astragaloside IV on immune function of regulatory T cell mediated by high mobility group box 1 protein in vitro.
  Huang LF, Yao YM, Li JF, Zhang SW, Li WX, Dong N, Yu Y, Sheng ZY.Fitoterapia. 2012 Dec;83(8):1514-22. doi: 10.1016/j.fitote.2012.08.019. Epub 2012 Sep 5.
• 10. HPLC-MS/MS analysis of a traditional Chinese medical formulation of Bu-Yang-Huan-Wu-Tang and its pharmacokinetics after oral administration to rats.
  Shaw LH, Lin LC, Tsai TH.PLoS One. 2012;7(8):e43848. doi: 10.1371/journal.pone.0043848. Epub 2012 Aug 29.
• 11. Chemical and biological assessment of Angelica herbal decoction: comparison of different preparations during historical applications.
  Zhang WL, Zheng KY, Zhu KY, Zhan JY, Bi CW, Chen JP, Du CY, Zhao KJ, Lau DT, Dong TT, Tsim KW.Phytomedicine. 2012 Aug 15;19(11):1042-8. doi: 10.1016/j.phymed.2012.07.009. Epub 2012 Aug 16.
• 12. Tanshinone IIA and astragaloside IV promote the migration of mesenchymal stem cells by up-regulation of CXCR4.
  Xie J, Wang H, Song T, Wang Z, Li F, Ma J, Chen J, Nan Y, Yi H, Wang W.Protoplasma. 2012 Aug 8. [Epub ahead of print]
• 13. Astragaloside IV alleviates hypoxia/reoxygenation-induced neonatal rat cardiomyocyte injury via the protein kinase a pathway.
  Zhang DW, Bian ZP, Xu JD, Wu HF, Gu CR, Zhou B, Chen XJ, Yang D.Pharmacology. 2012;90(1-2):95-101. doi: 10.1159/000339476. Epub 2012 Jul 12.
• 14. Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo.
  Gui D, Guo Y, Wang F, Liu W, Chen J, Chen Y, Huang J, Wang N.PLoS One. 2012;7(6):e39824. doi: 10.1371/journal.pone.0039824. Epub 2012 Jun 22.
• 15. [Inhibitory effects of astragaloside IV on cytochrome P450 enzyme of rat liver microsomes].
  Shan W, Zhang Y, Zhu J, Shao Q, Fan X.Zhongguo Zhong Yao Za Zhi. 2012 Jan;37(1):85-8. Chinese.
• 16. The membrane permeability of Astragali Radix-derived formononetin and calycosin is increased by Angelicae Sinensis Radix in Caco-2 cells: a synergistic action of an ancient herbal decoction Danggui Buxue Tang.
  Zheng KY, Choi RC, Guo AJ, Bi CW, Zhu KY, Du CY, Zhang ZX, Lau DT, Dong TT, Tsim KW.J Pharm Biomed Anal. 2012 Nov;70:671-9. doi: 10.1016/j.jpba.2012.05.018. Epub 2012 May 31.
• 17. Astragaloside IV Downregulates β-Catenin in Rat Keratinocytes to Counter LiCl-Induced Inhibition of Proliferation and Migration.
  Li FL, Li X, Wang YF, Xiao XL, Xu R, Chen J, Fan B, Xu WB, Geng L, Li B.Evid Based Complement Alternat Med. 2012;2012:956107. doi: 10.1155/2012/956107. Epub 2012 May 28.
• 18. Isolation of Anti-inflammatory Fractions and Compounds from the Root of Astragalus membranaceus.
  Lai PK, Chan JY, Cheng L, Lau CP, Han SQ, Leung PC, Fung KP, Lau CB.Phytother Res. 2012 Jun 13. doi: 10.1002/ptr.4759. [Epub ahead of print]
• 19. Topical astragaloside IV-releasing hydrogel improves healing of skin wounds in vivo.
  Peng LH, Chen X, Chen L, Li N, Liang WQ, Gao JQ.Biol Pharm Bull. 2012;35(6):881-8.
• 20. Pharmacokinetic evidence on contribution of intestinal bacterial conversion to beneficial effects of astragaloside IV, a marker compound of Astragali Radix, in traditional oral use of the herb.
  Zhou RN, Song YL, Ruan JQ, Wang YT, Yan R.Drug Metab Pharmacokinet. 2012 May 29. [Epub ahead of print]